Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013141 · ClinicalTrials.gov registry record · Phase 1
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
A Phase 1 study, sponsored by Cumberland Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02013141 is a Phase 1 study that was terminated before completion, run by Cumberland Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02013141, a Phase 1 study, was terminated before completion, sponsored by Cumberland Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children, and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV) over 60 minutes
Interventions
- DRUG Telavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-12 |
| Est. Completion | 2021-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013141
The ClinicalTrials.gov registry entry for NCT02013141 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telavancin is the first listed.
NCT02013141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02013141 about?
NCT02013141 is a clinical study titled "Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)". This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children, and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV) over 60 minutes
What is the current status of trial NCT02013141?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2014-12. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02013141?
The interventions under investigation include: Telavancin (DRUG).
Who is sponsoring clinical trial NCT02013141?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.